Show simple item record

dc.contributor.authorMurphy, C L
dc.contributor.authorAwan, S
dc.contributor.authorSullivan, M O
dc.contributor.authorChavrimootoo, S
dc.contributor.authorBannon, C
dc.contributor.authorMartin, L
dc.contributor.authorDuffy, T
dc.contributor.authorMurphy, E
dc.contributor.authorBarry, M
dc.date.accessioned2015-07-07T14:27:23Zen
dc.date.available2015-07-07T14:27:23Zen
dc.date.issued2015-01en
dc.identifier.citationMajor cost savings associated with biologic dose reduction in patients with inflammatory arthritis. 2015, 108 (1):19-21 Ir Med Jen
dc.identifier.issn0332-3102en
dc.identifier.pmid25702349en
dc.identifier.urihttp://hdl.handle.net/10147/559162en
dc.description.abstractThe purpose of this study was to explore whether patients with Inflammatory Arthritis (IA) (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS)) would remain in remission following a reduction in biologic dosing frequency and to calculate the cost savings associated with dose reduction. This prospective non-blinded non-randomised study commenced in 2010. Patients with Inflammatory Arthritis being treated with a biologic agent were screened for disease activity. A cohort of those in remission according to standardized disease activity indices (DAS28 < 2.6, BASDAI < 4) was offered a reduction in dosing frequency of two commonly used biologic therapies (etanercept 50 mg once per fortnight instead of weekly, adalimumab 40 mg once per month instead of fortnightly). Patients were assessed for disease activity at 3, 6, 12, 18 and 24 months following reduction in dosing frequency. Cost saving was calculated. 79 patients with inflammatory arthritis in remission were recruited. 57% had rheumatoid arthritis (n = 45), 13% psoriatic arthritis (n = 10) and 30% ankylosing spondylitis (n = 24). 57% (n = 45) were taking etanercept and 43% (n = 34) adalimumab. The percentage of patients in remission at 24 months was 56% (n = 44). This resulted in an actual saving to the state of approximately 600,000 euro over two years. This study demonstrates the reduction in biologic dosing frequency is feasible in Inflammatory Arthritis. There was a considerable cost saving at two years. The potential for major cost savings in biologic usage should be pursued further.
dc.language.isoenen
dc.publisherIrish Medical Journalen
dc.rightsArchived with thanks to Irish medical journalen
dc.subjectMEDICINESen
dc.subjectARTHRITISen
dc.subject.meshAdulten
dc.subject.meshAnti-Inflammatory Agentsen
dc.subject.meshAntibodies, Monoclonal, Humanizeden
dc.subject.meshArthritisen
dc.subject.meshCost Savingsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshImmunoglobulin Gen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshProspective Studiesen
dc.subject.meshReceptors, Tumor Necrosis Factoren
dc.subject.meshTreatment Outcomeen
dc.titleMajor cost savings associated with biologic dose reduction in patients with inflammatory arthritis.en
dc.typeArticleen
dc.identifier.journalIrish medical journalen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
refterms.dateFOA2018-08-26T22:12:11Z
html.description.abstractThe purpose of this study was to explore whether patients with Inflammatory Arthritis (IA) (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS)) would remain in remission following a reduction in biologic dosing frequency and to calculate the cost savings associated with dose reduction. This prospective non-blinded non-randomised study commenced in 2010. Patients with Inflammatory Arthritis being treated with a biologic agent were screened for disease activity. A cohort of those in remission according to standardized disease activity indices (DAS28 < 2.6, BASDAI < 4) was offered a reduction in dosing frequency of two commonly used biologic therapies (etanercept 50 mg once per fortnight instead of weekly, adalimumab 40 mg once per month instead of fortnightly). Patients were assessed for disease activity at 3, 6, 12, 18 and 24 months following reduction in dosing frequency. Cost saving was calculated. 79 patients with inflammatory arthritis in remission were recruited. 57% had rheumatoid arthritis (n = 45), 13% psoriatic arthritis (n = 10) and 30% ankylosing spondylitis (n = 24). 57% (n = 45) were taking etanercept and 43% (n = 34) adalimumab. The percentage of patients in remission at 24 months was 56% (n = 44). This resulted in an actual saving to the state of approximately 600,000 euro over two years. This study demonstrates the reduction in biologic dosing frequency is feasible in Inflammatory Arthritis. There was a considerable cost saving at two years. The potential for major cost savings in biologic usage should be pursued further.


Files in this item

Thumbnail
Name:
Article7853.pdf
Size:
21.87Kb
Format:
PDF
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record